These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 25613182)

  • 1. Changes of dopamine transporter availability in depressed patients with and without anhedonia: a 123I-N-ω-fluoropropyl-carbomethoxy-3β- (4-Iodophenyl)tropane SPECT study.
    Camardese G; De Risio L; Di Nicola M; Pucci L; Cocciolillo F; Bria P; Giordano A; Janiri L; Di Giuda D
    Neuropsychobiology; 2014; 70(4):235-43. PubMed ID: 25613182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Striatal dopamine transporter levels in patients with REM sleep behavior disorder: assessment with 123I-FP-CIT SPECT].
    Mossa EP; Niccoli Asabella A; Iuele F; Stabile Ianora AA; Giganti M; Rubini G
    Recenti Prog Med; 2012 Nov; 103(11):500-4. PubMed ID: 23096739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients.
    Zaaijer ER; van Dijk L; de Bruin K; Goudriaan AE; Lammers LA; Koeter MW; van den Brink W; Booij J
    Psychopharmacology (Berl); 2015 Jul; 232(14):2597-607. PubMed ID: 25757673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic dysfunction in the left putamen of patients with major depressive disorder.
    D'Onofrio AM; Pizzuto DA; Batir R; Perrone E; Cocciolillo F; Cavallo F; Kotzalidis GD; Simonetti A; d'Andrea G; Pettorruso M; Sani G; Di Giuda D; Camardese G
    J Affect Disord; 2024 Jul; 357():107-115. PubMed ID: 38636713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.
    Iranzo A; Valldeoriola F; Lomeña F; Molinuevo JL; Serradell M; Salamero M; Cot A; Ros D; Pavía J; Santamaria J; Tolosa E
    Lancet Neurol; 2011 Sep; 10(9):797-805. PubMed ID: 21802993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
    Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
    J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striatal presynaptic dopaminergic dysfunction in gambling disorder: A
    Pettorruso M; Martinotti G; Cocciolillo F; De Risio L; Cinquino A; Di Nicola M; Camardese G; Migliara G; Moccia L; Conte E; Janiri L; Di Giuda D
    Addict Biol; 2019 Sep; 24(5):1077-1086. PubMed ID: 30226290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: a preliminary report.
    Di Giuda D; Calcagni ML; Totaro M; Cocciolillo F; Piano C; Soleti F; Fasano A; Cioni B; Bentivoglio AR; Giordano A
    Nucl Med Commun; 2012 Sep; 33(9):933-40. PubMed ID: 22735298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects.
    Booij J; de Jong J; de Bruin K; Knol R; de Win MM; van Eck-Smit BL
    J Nucl Med; 2007 Mar; 48(3):359-66. PubMed ID: 17332612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
    Lorberboym M; Djaldetti R; Melamed E; Sadeh M; Lampl Y
    J Nucl Med; 2004 Oct; 45(10):1688-93. PubMed ID: 15471834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striatal Dopamine Transporter Modulation After Rotigotine: Results From a Pilot Single-Photon Emission Computed Tomography Study in a Group of Early Stage Parkinson Disease Patients.
    Rossi C; Genovesi D; Marzullo P; Giorgetti A; Filidei E; Corsini GU; Bonuccelli U; Ceravolo R
    Clin Neuropharmacol; 2017; 40(1):34-36. PubMed ID: 27941527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment with haloperidol reduces (123)I-FP-CIT binding to the dopamine transporter in the rat striatum: an in vivo imaging study with a dedicated small-animal SPECT camera.
    Nikolaus S; Antke C; Kley K; Beu M; Wirrwar A; Müller HW
    J Nucl Med; 2009 Jul; 50(7):1147-52. PubMed ID: 19525450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson's disease.
    Rektorova I; Srovnalova H; Kubikova R; Prasek J
    Mov Disord; 2008 Aug; 23(11):1580-7. PubMed ID: 18618663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Test-retest reproducibility of extrastriatal binding with
    Matsuoka K; Yasuno F; Shinkai T; Miyasaka T; Takahashi M; Kiuchi K; Kosaka J; Inoue M; Kichikawa K; Hasegawa M; Kishimoto T
    Psychiatry Res Neuroimaging; 2016 Dec; 258():10-15. PubMed ID: 27814458
    [No Abstract]   [Full Text] [Related]  

  • 17. Altered serotonin and dopamine transporter availabilities in brain of depressed patients upon treatment with escitalopram: A [123 I]β-CIT SPECT study.
    Rominger A; Cumming P; Brendel M; Xiong G; Zach C; Karch S; Tatsch K; Bartenstein P; la Fougère C; Koch W; Pogarell O
    Eur Neuropsychopharmacol; 2015 Jun; 25(6):873-81. PubMed ID: 25819144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SPECT-evaluation of the monoamine uptake site ligand [123I](1R)-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane ([123I]beta-CIT) in untreated patients with suspicion of Parkinson disease.
    Eising EG; Müller TT; Zander C; Kuhn W; Farahati J; Reiners C; Coenen HH
    J Investig Med; 1997 Oct; 45(8):448-52. PubMed ID: 9394097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 123I-FP-CIT SPECT imaging of the dopaminergic state. Visual assessment of dopaminergic degeneration patterns reflects quantitative 2D operator-dependent and 3D operator-independent techniques.
    Kahraman D; Eggers C; Holstein A; Schneider C; Pedrosa DJ; Dietlein M; Kobe C; Timmermann L; Schmidt M
    Nuklearmedizin; 2012; 51(6):244-51. PubMed ID: 22526237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of [123I]FP-CIT binding to the dopamine transporter (DAT) in healthy mouse striatum using dedicated small animal SPECT imaging: feasibility, optimization and validation.
    Greco A; Zannetti A; Pappatà S; Albanese S; Coda AR; Ragucci M; Nardelli A; Brunetti A; Cuocolo A; Salvatore M
    Q J Nucl Med Mol Imaging; 2018 Mar; 62(1):112-117. PubMed ID: 26329495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.